Patient characteristics according to randomization
| . | Single-unit UCB (n = 74) . | Double-unit UCB (n = 77) . | P . |
|---|---|---|---|
| Sex | .84 | ||
| Male | 45 (60.8) | 48 (62.3) | |
| Female | 29 (39.2) | 29 (37.7) | |
| Age | .90 | ||
| 0-9 y | 39 (52.7) | 43 (55.8) | |
| 10-24 y | 28 (37.8) | 28 (36.4) | |
| 25-35 y | 7 (9.5) | 6 (7.8) | |
| Age | .94 | ||
| <18 y | 59 (79.7) | 61 (79.2) | |
| ≥18 y | 15 (20.3) | 16 (20.8) | |
| Diagnosis | .77 | ||
| ALL | 45 (60.8) | 45 (58.4) | |
| AML/MDS | 29 (39.2) | 32 (41.6%) | |
| Hematologic status at randomization | .10 | ||
| CR 1 | 31 (41.9) | 42 (54.5) | |
| CR ≥2 | 41 (55.4) | 30 (39.0) | |
| MDS | 2 (2.7) | 5 (6.5) | |
| Transplanted patients | |||
| Conditioning regimen | n = 68 | n = 69 | |
| FluTBICy | 41 (60.3) | 42 (60.9) | .94 |
| BuCyATG | 27 (39.7) | 27 (39.1) | |
| Interval from randomization to HSCT (days) | |||
| Mean ± SEM | 38.9 ± 1.9 | 39.7 ± 2.1 | .20 |
| Median (range) | 35.5 (13-87) | 34 (17-83) | .78 |
| Follow-up duration from HSCT (days) | |||
| Mean ± SEM | 781 ± 66.5 | 815 ± 66.6 | .71 |
| Median (range) | 709 (15-1930) | 800 (24-1814) | .73 |
| . | Single-unit UCB (n = 74) . | Double-unit UCB (n = 77) . | P . |
|---|---|---|---|
| Sex | .84 | ||
| Male | 45 (60.8) | 48 (62.3) | |
| Female | 29 (39.2) | 29 (37.7) | |
| Age | .90 | ||
| 0-9 y | 39 (52.7) | 43 (55.8) | |
| 10-24 y | 28 (37.8) | 28 (36.4) | |
| 25-35 y | 7 (9.5) | 6 (7.8) | |
| Age | .94 | ||
| <18 y | 59 (79.7) | 61 (79.2) | |
| ≥18 y | 15 (20.3) | 16 (20.8) | |
| Diagnosis | .77 | ||
| ALL | 45 (60.8) | 45 (58.4) | |
| AML/MDS | 29 (39.2) | 32 (41.6%) | |
| Hematologic status at randomization | .10 | ||
| CR 1 | 31 (41.9) | 42 (54.5) | |
| CR ≥2 | 41 (55.4) | 30 (39.0) | |
| MDS | 2 (2.7) | 5 (6.5) | |
| Transplanted patients | |||
| Conditioning regimen | n = 68 | n = 69 | |
| FluTBICy | 41 (60.3) | 42 (60.9) | .94 |
| BuCyATG | 27 (39.7) | 27 (39.1) | |
| Interval from randomization to HSCT (days) | |||
| Mean ± SEM | 38.9 ± 1.9 | 39.7 ± 2.1 | .20 |
| Median (range) | 35.5 (13-87) | 34 (17-83) | .78 |
| Follow-up duration from HSCT (days) | |||
| Mean ± SEM | 781 ± 66.5 | 815 ± 66.6 | .71 |
| Median (range) | 709 (15-1930) | 800 (24-1814) | .73 |
Data are presented as n (%) of patients, unless otherwise indicated.
CR, complete remission.